Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol

NCT06882057 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

3000

Enrollment

OTHER

Sponsor class

Conditions

Acute Lymphoblastic Leukemia ALL
Childhood Leukemia, Acute Lymphoblastic
B Cell Acute Lymphoblastic Leukemia (B-ALL)

Interventions

DRUG: Blinatumomab
DRUG: Reinduction-2 omission
DRUG: Chemo-light Maintenance 2

Sponsor

Institute of Hematology & Blood Diseases Hospital, China